HEALTH TECHNOLOGY

H2O.ai Showcases Healthcare and Life Sciences Leadership with Customer Successes, Breadth of AI Apps at HIMSS 2022

H2O.ai | March 14, 2022

H2O.ai, the AI Cloud leader, announced it has expanded its healthcare capabilities, now offering 40 AI applications across population health, precision medicine, public health and intelligent supply chain, supporting customers throughout the healthcare ecosystem including Bon Secours Mercy Health and Kaiser Permanente.
The company will demonstrate its technologies at the healthcare industry’s flagship technology conference, HIMSS, in Booth No. 8141, March 15-17 at the Orange County Convention Center in Orlando.

Healthcare and life sciences organizations have been stretched thin over the past few years and are actively looking for new technologies to streamline operations and improve patient outcomes across the private and public sectors. AI will empower physicians, hospital administrators, researchers and pharmaceutical companies with models and applications that produce more affordable, more accessible and more efficient healthcare. H2O.ai is at the forefront of this effort, helping organizations rapidly transform to improve health equity, access and care.

For example, the Center for Digital Health Innovation (CDHI) at the University of California, San Francisco (UCSF) is collaborating with H2O.ai on the development and training of AI algorithms that automate the processing of the 1.4 million faxed patient referrals and other documents that UCSF’s health system receives annually. The algorithms identify, classify and prioritize document types. For referrals, the AI extracts key patient data, history and relevant health information that will assist staff and eliminate manual data entry and validation tasks.

AI in healthcare has the potential to dramatically improve the operational processes that can prevent patients from getting care quickly, at the right place, and from the right provider. Our work with H2O.ai for health document handling is just one aspect of the transformation in the ways patients access and receive care.”

Alon Konchitsky, associate director for data science and machine learning at CDHI

H2O.ai has developed 40 AI apps supporting various components of the healthcare ecosystem, including

Population Health

H2O.ai’s Covid-19 hospital occupancy simulator allows hospital administrators to track, predict and manage Covid-19-related hospital admissions by U.S. county. The company also has a pop-up predictor that allows for the quick identification of specific addresses in the U.S. that would be most suitable for temporary vaccination clinics, mobile testing centers, public education stands and more. H2O.ai’s customers - leading providers, payers and accountable care organizations (ACOs) - are developing and deploying AI models and apps around patient no shows, 30-day readmission predictors, risk stratification and omni-channel patient engagement NLP.

Precision Medicine

H2O.ai has developed a gene mutation app, a machine learning-powered patient risk assessment application that uses the Snowflake Data Cloud and the H2O AI Cloud to bring intelligent clinical decision support directly to clinicians. In another use case, H2O.ai’s gene expression tumor classification app uses gene expression information from patient biopsies to evaluate the risk of malignancy and understand how common the risk has been among past patients.

“H2O AI Cloud, integrated with the Snowflake Data Cloud, is making it easier for health organizations to rapidly develop precision medicine solutions,” said Todd Crosslin, Global Head of Healthcare and Life Sciences at Snowflake. “The Gene mutation app is just the beginning of our health partnership and our ability to deliver improved care and patient outcomes.”

Public Health

The company’s Covid-19 forecasting application enables hospital staff, policymakers and others to predict the next wave of infection as well as potential case and death rates. H2O.ai also provides a vaccine sentiment tool that leverages natural language processing (NLP) to understand the sentiment around Covid-19 vaccines, and the company is currently working with leaders to address the risks and care associated with PASC (AKA Long COVID).

Intelligent Supply Chain

To provide intelligent supply chain support, H2O.ai’s route optimizer application helps health manufacturers best optimize transportation routes to ensure products arrive on time and to standard. H2O.ai also has developed an order and inventory management app to aid health manufacturers’ inefficient warehouse and inventory management decisions.

Avoiding AI “Pilot-itis”

Many health and life sciences organizations are struggling to implement AI projects that improve patient outcomes, reduce costs and more. Through its expertise and the H2O AI Cloud platform, H2O.ai is able to break companies out of the pilot cycle and successfully take them to AI maturity to deliver impactful results. In fact, H2O.ai has experienced an increase in healthcare customers moving from the pilot phase to full-blown production AI programs.

“Artificial Intelligence and deep learning are not only driving the latest innovations in medicine but also are enabling healthcare organizations to connect fragmented data into a format that can be used to improve operational efficiency and provide more user-centric patient experiences,” said Sri Ambati, CEO and co-founder of H2O.ai. “From its use in drug discovery and forecasting the next COVID-19 variant to streamlining supply chain operations and reducing healthcare worker churn, AI will have a significant impact on democratizing health and improving patient outcomes.”

About H2O.ai
H2O.ai is the leading AI cloud company, on a mission to democratize AI for everyone. Customers use the H2O AI Cloud platform to rapidly solve complex business problems and accelerate the discovery of new ideas. H2O.ai is the trusted AI provider to more than 20,000 global organizations, including AT&T, Bon Secours Mercy Health, Capital One, Commonwealth Bank of Australia, GlaxoSmithKline, Hitachi, Kaiser Permanente, Procter & Gamble, PayPal, PwC, Reckitt, Unilever and Walgreens, over half of the Fortune 500 and one million data scientists. Goldman Sachs, NVIDIA and Wells Fargo are not only customers and partners, but strategic investors in the company. H2O.ai’s customers have honored the company with a Net Promoter Score (NPS) of 78— the highest in the industry based on breadth of technology and deep employee expertise. The world’s top 20 Kaggle Grandmasters (the community of best-in-the-world machine learning practitioners and data scientists) are employees of H2O.ai. A strong AI for Good ethos to make the world a better place and Responsible AI drive the company’s purpose. Please join our movement at H2O.ai.

Spotlight

Data and Perspective about a High Risk Patient Group

Spotlight

Data and Perspective about a High Risk Patient Group

Related News

HEALTH TECHNOLOGY

Canon strengthens medical business with establishment of Canon Healthcare USA, INC.

Canon Medical Systems USA | November 28, 2022

Canon Inc. announced that the company has decided to establish a new subsidiary, to be named Canon Healthcare USA, INC. By strengthening its presence in the highly influential American medical market, Canon aims to accelerate the growth of its medical business. The Canon group is currently working towards a grand strategic transformation of its business portfolio in order to realize future growth. With the announcement of Phase VI, the latest in the company’s Excellent Global Corporation Plan series of 5-year management programs, Canon’s primary objective is to “thoroughly strengthen business competitiveness.” Under this slogan, Canon is striving to increase its competitiveness in various spheres of the medical industry, including diagnostics such as CT, MRI, diagnostic ultrasound systems, as well as medical component businesses such as X-ray tubes, X-ray detectors and key MRI components. In addition, the company is making strides in the field of healthcare IT and in vitro diagnostics. One of the most pressing challenges for Canon’s medical business has been the need to strengthen its presence in the American medical industry, which is extremely influential on the global market. Canon has decided to consider the greater Cleveland area, a key hub in the country’s medical industry as a candidate location for establishing Canon Healthcare USA, INC. in order to strengthen the company’s competitive presence in the global market. With the establishment of Canon Healthcare USA, INC., Canon will transfer a portion of its marketing operations, incubated at the Global Headquarters over Canon’s long history. These operations will transfer to the Global Marketing Center, to be established in January of 2023, in order to strengthen upstream marketing1. By establishing a network with medical institutions on the front lines of treatment and achieving a greater understanding of the market, Canon will develop and propose products and solutions that address the trends and needs of the medical market. Among such efforts is the commencement of joint research with American medical institutions on the practical application of X-ray CT systems utilizing photon counting detection modules, with the goal of capturing the No.1 share of the global CT market at an early stage. In addition, Canon Medical Systems USA the U.S. subsidiary of Canon Medical Systems Corporation will transfer a portion of its product sales and service operations to Canon Healthcare USA. This will integrate operations with downstream marketing2, thereby enabling the company to focus on increasing its share of medical diagnostic systems in the American market. The Cleveland area, one of the candidate locations, is home to the headquarters and factory of Quality Electrodynamics, LLC which develops and manufactures MRI key components and was welcomed into the Canon Group in 2019. By placing QED under the umbrella of Canon Healthcare USA, Canon will aim to increase coordination between its system and component businesses. Furthermore, Canon Medical will take over the advanced technology research activities that Canon has been conducting with Massachusetts General Hospital and Brigham Women’s Hospital at the Healthcare Optics Research Laboratory in Boston for 10 years, and will promote joint research aimed at commercialization in collaboration with the Global Marketing Center. In addition, Canon is considering the possibility of expanding U.S.-based development, manufacturing and other capabilities, with the goal of further strengthening its business in the country. The establishment of this new company and expansion of business operations is expected to require USD $300 million of investment capital. This investment will empower Canon’s medical business to grow by deepening its understanding of customer and market needs, as well as redouble its efforts in the American market, thereby contributing to the global medical industry.

Read More

FUTURE OF HEALTHCARE

BioIntelliSense Joins Polaris Dawn Mission to Advance Understanding of Human Health in Space

BIOINTELLISENSE | November 15, 2022

BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, today announced its partnership with the Translational Research Institute for Space Health (TRISH) to further understanding of human health in space. The BioButton® medical grade wearable device will be used for commercial spaceflight research programs and notably during the upcoming five-day Polaris Dawn mission. This historic mission will be flown by SpaceX and is scheduled to launch after March 2023. Medical and scientific research on human health in space promotes the advancement of translational technologies by adapting known technology for space applications, and by using space-based insights to improve healthcare at home. “BioIntelliSense has proudly gained industry recognition for its innovative and comprehensive portfolio of continuous multi-parameter monitoring solutions for application in the acute care environment, at home settings and now, in the next frontier of space, As a lifelong space exploration enthusiast, it is a tremendous honor to be working with TRISH on health research that can benefit astronauts and crews during commercial space flight and for the BioButton devices to be part of the upcoming Polaris Dawn mission.” -James Mault, MD, founder and CEO of BioIntelliSense The BioButton multi-parameter device is designed to be worn on the upper left chest and will passively capture trending physiologic and movement data from the Polaris Dawn crew during its milestone mission. The future of healthcare is here. Today, the BioIntelliSense Data-as-a-Service (DaaS) platform and clinical intelligence solution is commercially available and rapidly adopted by acute and post-acute providers in the U.S. along with select international markets. TRISH is proud to partner with innovative healthcare technology leaders like BioIntelliSense as we further our understanding of human health in space, Our EXPAND (Enhancing eXploration and ANalog Definition) commercial spaceflight health research platform provides unique opportunities to rapidly test technologies in orbit, as well as collect new datapoints on the health impact of spaceflight for a wider, more diverse population,said James Hury, TRISH Chief Innovation Officer and Deputy Director. BioIntelliSense (Booth #5025) and TRISH (Space Health Pavilion #2636) will be showcasing the BioButton wearable device and clinical intelligence solution at the premier HLTH 2022 conference November 13 – 16 in Las Vegas, NV. ABOUT BIOINTELLISENSE BioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence for remote patient monitoring (RPM). Its medical-grade Data-as-a-Service (DaaS) platform seamlessly captures multi-parameter vital signs, physiological biometrics and symptomatic events through an effortless patient experience. The medical-grade BioButton® wearable device makes remote monitoring and early detection simple. Through the platform’s advanced analytics, clinicians have access to high-resolution patient trending and reporting to enable medical grade remote care from in-hospital to home. ABOUT TRANSLATIONAL RESEARCH INSTITUTE for SPACE HEALTH (TRISH) Led by Baylor College of Medicine’s Center for Space Medicine, TRISH is a consortium that includes partners Caltech and MIT. NASA recently awarded the Institute a six-year extension to further its work by delivering disruptive solutions to mitigate biomedical risks for human exploration while advancing terrestrial health technologies.

Read More

HEALTH TECHNOLOGY

Gradient AI Acquires Healthcare Analytics Business Unit from Prognos Health to Expand Medical Underwriting Offering

Gradient AI and Prognos Health | October 11, 2022

Self Insurance Institute of America conference -October 10, 2022- Gradient AI, a leading enterprise software provider of artificial intelligence (AI) solutions in the insurance industry announced that it has acquired Prognos Health’s analytics business underwriting unit to leverage data from the company’s large collection of integrated medical records and lab data via its real-world data marketplace. The acquisition will enable Gradient AI to expand its medical database capabilities by integrating Prognos Health’s data with SAIL™, Gradient AI’s leading medical underwriting solution. Medical records on 325 million de-identified U.S. patients can be accessed through the Prognos Marketplace. In addition to retrieving medical and prescription claims data customers will now have access to lab data, which has been a missing factor for many insurers when predicting group risk. According to the Centers for Disease Control and Prevention (CDC), 70% of today’s medical decisions depend on laboratory test results because they are among the best indicators of disease severity and progression. With the acquisition, Gradient AI will become the only company in the group medical insurance market to provide medical, prescription, and lab data from a single source. Insurers will benefit by having further insight into group members' health for more informed risk assessment and improved underwriting accuracy. “The acquisition of Prognos underwriting business unit is a game changer. Our combined solution will provide a holistic picture of group health risk that has never before been possible. Insurers will now have a single point of access to multiple data sources, covering medical, prescription and lab data improving their abilities to project group health assessments and costs with much greater confidence.” Stan Smith, CEO and founder, Gradient AI Gradient AI aspires to continue its innovation in assessing group health risks. In the future, the company plans to expand its data sources to include information from Electronic Health Records and claims-based patient population data. “We are excited to join forces with Gradient AI to create a next-generation industry leading solution for group health insurance,” said Sundeep Bhan, co-founder and CEO, Prognos Health. “Gradient AI is a clear leader in healthcare analytics underwriting. Prognos looks forward to supporting the rapid innovation at Gradient AI by leveraging the most relevant data from the Prognos Marketplace. With the sale of the underwriting business unit, Prognos will continue to focus on our real-word data marketplace and democratizing data to improve health.” About Prognos Health Prognos Health’s mission is to democratize data to improve health. Prognos is focused on enabling data accessibility for everyone by leveraging technology and our clinical experience. We are removing data silos and fragmentation by linking, normalizing and standardizing data. We allow data to flow more freely and help organizations make the best data-informed decisions by simplifying and streamlining access to fit-for-purpose, multi-dimensional real-world data sets. Prognos is the leading real-world data marketplace with integrated RWD on 325M patients. All data purchased is available on the Datavant token, making it interoperable with other patient-level data that has been tokenized using Datavant. About Gradient AI Gradient AI is a leading provider of proven artificial intelligence (AI) solutions for the insurance industry. Its solutions improve loss ratios and profitability by predicting underwriting and claim risks with greater accuracy, as well as reducing quote turnaround times and claim expenses through intelligent automation. Unlike other solutions that use a limited claims and underwriting dataset, Gradient's software-as-a-service (SaaS) platform leverages a vast dataset comprised of tens of millions of policies and claims. It also incorporates numerous other features including economic, health, geographic and demographic information. Customers include some of the most recognized insurance carriers, MGAs, TPAs, risk pools, PEOs and large self-insureds across all major lines of insurance. By using Gradient AI’s solutions, insurers of all types achieve a better return on risk.

Read More